Resuscitation Therapeutics
A startup (founded 2017) focused on developing therapies, diagnostic assays, and automated management strategies for life‑threatening acute conditions (cardiac arrest, septic shock, hemorrhagic shock) through preclinical translational research, device/software prototypes, and clinical development.
Industries
Nr. of Employees
small (1-50)
Resuscitation Therapeutics
Products
Autonomous circulatory management research prototype
A research prototype for autonomous hemodynamic management designed to continuously optimize the balance between systemic blood flow and vascular resistance to maintain organ perfusion in septic shock and related conditions.
Plasma cytochrome c assay (electrochemiluminescence format)
High-sensitivity electrochemiluminescence immunoassay developed to quantify plasma cytochrome c as a marker of mitochondrial injury for preclinical and clinical studies.
ERYCA Phase 3 clinical trial (protocol)
Phase 3 clinical trial protocol designed to evaluate administration of erythropoietin during CPR for out‑of‑hospital cardiac arrest with 72‑hour survival as the primary endpoint; includes multiple clinical and biomarker secondary endpoints.
Autonomous circulatory management research prototype
A research prototype for autonomous hemodynamic management designed to continuously optimize the balance between systemic blood flow and vascular resistance to maintain organ perfusion in septic shock and related conditions.
Plasma cytochrome c assay (electrochemiluminescence format)
High-sensitivity electrochemiluminescence immunoassay developed to quantify plasma cytochrome c as a marker of mitochondrial injury for preclinical and clinical studies.
ERYCA Phase 3 clinical trial (protocol)
Phase 3 clinical trial protocol designed to evaluate administration of erythropoietin during CPR for out‑of‑hospital cardiac arrest with 72‑hour survival as the primary endpoint; includes multiple clinical and biomarker secondary endpoints.
Services
Design and delivery of real-time multi-channel data acquisition, closed-loop intervention routines, and customizable analysis/reporting for preclinical investigators.
Design and delivery of real-time multi-channel data acquisition, closed-loop intervention routines, and customizable analysis/reporting for preclinical investigators.
Expertise Areas
- Preclinical translational research
- Resuscitation pharmacology
- Hemodynamic monitoring and automated control
- Biomarker assay development
Key Technologies
- Swine and rodent preclinical models
- Electrochemiluminescence immunoassay for plasma biomarkers
- Real-time multi-channel data acquisition
- Programmable closed-loop control systems
News & Updates
Received favorable feedback from the FDA Center for Drug Evaluation and Research after submission of a pre-IND briefing package for erythropoietin development (meeting documented, Sept 9, 2022).
Filed a U.S. provisional patent application for the Autonomous Circulatory Management System (research prototype).
Founder received the Asmund S. Laerdal Memorial Lecture Award for research in resuscitation and critical care medicine.
Received favorable feedback from the FDA Center for Drug Evaluation and Research after submission of a pre-IND briefing package for erythropoietin development (meeting documented, Sept 9, 2022).
Filed a U.S. provisional patent application for the Autonomous Circulatory Management System (research prototype).
Founder received the Asmund S. Laerdal Memorial Lecture Award for research in resuscitation and critical care medicine.